2-Arachidonoylglycerol (2-AG)

Our opinion on this compoundNiche research probe

54/100

Canonical full-agonist endocannabinoid, indispensable reference probe for CB1/CB2 synaptic signaling work

Look, 2-AG is thirty years old and it’s still one of the more important compounds on any endocannabinoid bench. That tension is worth sitting with. Mechoulam and Sugiura independently identified it in 1995, and the subsequent three decades have mapped out its role in retrograde synaptic signaling with unusual precision for the field. It’s the principal full agonist at both CB1 and CB2, and unlike anandamide, it circulates at substantially higher concentrations in brain tissue, which is part of why it’s considered the dominant endocannabinoid signal in most circuits.

The mechanism is genuinely elegant even if it’s no longer novel. Calcium influx into a postsynaptic neuron drives diacylglycerol lipase (DAGL) activity, producing 2-AG on demand. That 2-AG diffuses retrogradely across the synapse, activates presynaptic CB1, and suppresses transmitter release. The result is either short-term or long-term depression depending on context. This retrograde endocannabinoid signaling is central to forms of synaptic plasticity that show up in fear extinction, appetite regulation, motor control, and pain processing. What we like about this mechanism is that it’s genuinely load-bearing in multiple systems simultaneously, which is rare for a single lipid mediator.

Here’s the thing about using 2-AG directly at the bench: the compound is chemically fragile. Spontaneous isomerization from the 2-position to the thermodynamically favored 1-position happens fast under normal handling conditions, and MAGL degrades it to arachidonic acid and glycerol with a half-life measured in minutes. Most serious investigators today reach for MAGL inhibitors like JZL184 or KML29 to elevate endogenous 2-AG rather than working with the exogenous lipid directly. Thats not a knock on 2-AG as a concept, but it does limit how often the neat compound itself actually comes out of the freezer in a live experiment.

On novelty, we have to be honest. Thirty years of active research mean there is no shortage of published mechanism. Where 2-AG retains clear value is as a reference standard and in acute ex vivo work where you need precisely defined CB1/CB2 full agonism, not the indirect elevation profile of a FAAH or MAGL inhibitor. For slice prep work, receptor binding displacement assays, and cell-based signaling cascade studies, the compound remains genuinely useful in a way that generic lipid precursors are not.

Translational signal is weak for 2-AG directly. The interesting therapeutic action in the eCB space runs through MAGL inhibitors currently in clinical investigation for neuroinflammation and pain, and through FAAH inhibitors with their own clinical history. 2-AG as a standalone research object is primarily of interest to groups already deep in endocannabinoid biology rather than as a broad therapeutic frontier. The 54 reflects exactly that positioning: important tool, mature mechanism, limited novelty, and a translational story that belongs to the enzymes rather than the lipid itself.

Novelty: 32
Mechanism promise: 58
In-category differentiation: 65
Evidence quality: 68
Translational signal: 38
Research bench value: 72

Rationale 2-AG earns its score on bench differentiation and evidence depth as the reference-standard full agonist for retrograde endocannabinoid signaling, but novelty is low after three decades of intense study and direct translational value is limited by rapid MAGL-mediated degradation; its real value is as a tool, not a therapeutic candidate.

Endocannabinoid (monoacylglycerol)

A monoacylglycerol endocannabinoid; the principal full agonist at CB1 and CB2 receptors and the higher-abundance endocannabinoid in brain.

Abstract

2-Arachidonoylglycerol (2-AG; CAS 53847-30-6; molecular formula C23H38O4; molecular weight 378.55) is a monoacylglycerol endocannabinoid identified by Mechoulam and Sugiura groups in 1995. The compound is a full agonist at both CB1 and CB2 receptors, with higher concentrations in brain than anandamide. Synthesis is calcium-dependent via diacylglycerol lipase (DAGL); degradation is via monoacylglycerol lipase (MAGL) producing arachidonic acid and glycerol. The on-demand synthesis-degradation kinetics produce phasic retrograde signaling, particularly at synapses where 2-AG mediates short-term and long-term presynaptic depression. Plasma half-life is short (minutes) owing to MAGL-mediated degradation. Used as the canonical full-agonist endocannabinoid in neuroscience research; pharmacological elevation is achieved via MAGL inhibitors (JZL184, KML29). The 2-AG signaling pathway is central to retrograde synaptic communication and is the primary mechanism for endocannabinoid-mediated neuroplasticity.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-324Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.